Portage Biotech Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of cancer. The company is dedicated to advancing its proprietary drug candidates through various stages of clinical development, aiming to address unmet medical needs in oncology. By leveraging its scientific expertise and strategic partnerships, Portage is engaged in researching and developing novel immunotherapies and personalized medicine approaches that aim to improve patient outcomes and enhance the efficacy of existing cancer treatments. Read More
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
The company is preparing to launch a first-in-human clinical trial for PORT-7 and is simultaneously advancing dose escalation for PORT-6, a selective A2A receptor inhibitor.
Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
A new wave of innovation is taking hold across the biotech and tech sectors, with four high-impact companies— Peraso Inc. (NASDAQ: PRSO), Lexicon Pharmaceuticals (NASDAQ: LXRX), Portage Biotech (NASDAQ: PRTG), and TransCode Therapeutics (NASDAQ: RNAZ) —each making strategic advances in their respective arenas: military-grade wireless, obesity treatment, cancer immunotherapy, and RNA-based oncology solutions. These breakthroughs represent critical inflection points for investors eyeing cutting-edge solutions backed by scientific validation, regulatory momentum, and untapped market potential.
